Home / Innere Medizin / Onkologie / ASCO 2019: Sensationelle Ergebnisse mit Chemo-freier Rezidiv-Therapie beim Ovarialkarzinom

ASCO 2019: Sensationelle Ergebnisse mit Chemo-freier Rezidiv-Therapie beim Ovarialkarzinom

Ein ASCO-Highlight für Univ.-Prof. Dr. Christian Marth, Leiter der Universitätsklinik für Frauenheilkunde, Innsbruck, ist die AVANOVA-2-Studie, deren Ergebnisse eine Chemo-freie Rezidiv-Therapie beim Ovarialkarzinom in Aussicht stellen. Weitere Gyn-Onko-News betrafen das Zervix- und Endometriumkarzinom.

Cookies aktivieren

Um das Video anzusehen, müssen Sie Statistikcookies akzeptieren.

Einstellungen verwalten
Abstracts, die im Video diskutiert werden:

Abstract 5501
Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).
Yoland Catherine Antill,

Abstract 5502
Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC).
Panagiotis A. Konstantinopoulos,

Abstract 5503
Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994.
Gemma Kenter,

Abstract 5508
EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study.
Claire Falandry

Abstract  5506
Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.
Richard T. Penson

Abstract  5505
Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24
Mansoor Raza Mirza